Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.

Description Area Preclinical Development Clinical Development
Development Preclinics Phase I Phase II Phase III
MP1032 - Psoriasis Dermatology          
MP1032 - Tendinopathy Musculoskeletal          
MP1032 - Arthrosis/Arthritis Musculoskeletal          
Non-disclosed Immunology          
MP1031 - Immunology Immunology          
MP1033 - Immunology Immunology          
MP1091 - IBD Gastrointestinal          
MP1105 - Anti-infective Anti-infective